{"nctId":"NCT00196326","briefTitle":"Open-label Study to Evaluate the Efficacy and Safety of an Extended-cycle, Low Dose Combination Oral Contraceptive","startDateStruct":{"date":"2005-06"},"conditions":["Contraception"],"count":2235,"armGroups":[{"label":"DR-1011","type":"EXPERIMENTAL","interventionNames":["Drug: DR-1011"]}],"interventions":[{"name":"DR-1011","otherNames":["levonorgestrel/ethinyl estradiol"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Premenopausal\n* Not pregnant or breastfeeding\n* Sexually active at risk of pregnancy\n\nExclusion Criteria:\n\n* Any contraindication to the use of oral contraceptives\n* Pregnancy within the last 3 months\n* Smoking \\> 10 cigarettes per day","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"40 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Annualized Pregnancy Rate (Pearl Index) For 91-Day Cycles by Cohort Using up to 14 Days Post-Last Combination Dose When Defining \"On Drug\" Pregnancy","description":"Pearl Index= ((100)\\*(number of pregnancies)\\*(4 cycles/year))/number of 91-day cycles completed.\n\nThe pregnancy rate included \"on-drug\" pregnancies, defined as those pregnancies for which the date of conception was on or after the date of first dose of study medication, but no more than 14 days after the date of last combination dose of study medication.\n\nPregnancy was defined as a positive pregnancy test verified by the study staff. The conception date was based on the ultrasound date. A pregnancy was not considered 'on drug' if conception clearly occurred prior to first dose of study medication, or more than 14 days after the date of last combination dose of study medication.\n\nThree denominators are reported;\n\n* excluding cycles where other birth control methods (BCMs) was used\n* all complete cycles\n* compliant-use (i.e. subject did not skip two or more consecutive pills or had a pattern of substantial non-compliance, or used a prohibited concomitant medication)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.77","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants With Treatment-Emergent Adverse Events","description":"Safety was assessed by summarizing adverse events recorded in the patient's daily diary and reported by subjects at each study visit, and by summarizing results of examination, vital signs and clinical laboratory values.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1742","spread":null}]}]}]},{"type":"PRIMARY","title":"Annualized Pregnancy Rate (Pearl Index) For 91-Day Cycles by Cohort Using up to 7 Days Post-Last Combination Dose When Defining \"On Drug\" Pregnancy","description":"Pearl Index= ((100)\\*(number of pregnancies)\\*(4 cycles/year))/number of 91-day cycles completed.\n\nThe pregnancy rate included \"on-drug\" pregnancies, defined as those pregnancies for which the date of conception was on or after the date of first dose of study medication, but no more than 7 days after the date of last combination dose of study medication.\n\nPregnancy was defined as a positive pregnancy test verified by the study staff. The conception date was based on the ultrasound date. A pregnancy was not considered 'on drug' if conception clearly occurred prior to first dose of study medication, or more than 7 days after the date of last combination dose of study medication.\n\nThree denominators are reported;\n\n* excluding cycles where other birth control methods (BCMs) was used\n* all complete cycles\n* compliant-use (i.e. subject did not skip two or more consecutive pills or had a pattern of substantial non-compliance, or used a prohibited concomitant medication)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.77","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":34,"n":2185},"commonTop":["HEADACHE","NASOPHARYNGITIS","DYSMENORRHOEA","NAUSEA","METRORRHAGIA"]}}}